Cargando…

Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

OBJECTIVE: Systematically evaluate the efficacy of physical ablation combined with TKI in the treatment of advanced non-small cell lung cancer (NSCLC). METHODS: We performed a comprehensive search of databases including OVID, PubMed, EMBASE, the Cochrane Library, and three Chinese databases (China N...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lu-Zhen, Wu, Jia-Ming, Chen, Ting, Zhao, Liang-Chen, Zhuang, Juan-Na, Hong, Hui-Si, Zhang, Ao, Zhang, Hua-Tang, Fang, Can-Tu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123993/
https://www.ncbi.nlm.nih.gov/pubmed/34055015
http://dx.doi.org/10.1155/2021/6624429
_version_ 1783693080003608576
author Li, Lu-Zhen
Wu, Jia-Ming
Chen, Ting
Zhao, Liang-Chen
Zhuang, Juan-Na
Hong, Hui-Si
Zhang, Ao
Zhang, Hua-Tang
Fang, Can-Tu
author_facet Li, Lu-Zhen
Wu, Jia-Ming
Chen, Ting
Zhao, Liang-Chen
Zhuang, Juan-Na
Hong, Hui-Si
Zhang, Ao
Zhang, Hua-Tang
Fang, Can-Tu
author_sort Li, Lu-Zhen
collection PubMed
description OBJECTIVE: Systematically evaluate the efficacy of physical ablation combined with TKI in the treatment of advanced non-small cell lung cancer (NSCLC). METHODS: We performed a comprehensive search of databases including OVID, PubMed, EMBASE, the Cochrane Library, and three Chinese databases (China National Knowledge Infrastructure, Wanfang Database, and Chongqing Weipu Database). The aim was to identify randomized controlled trials (RCT) investigating physical ablation as the treatment for advanced NSCLC. We also evaluated the methodological quality of the included studies and summarized the data extracted for meta-analysis with Review Manager 5.3. RESULTS: A total of 9 studies, including 752 patients, were evaluable. The meta-analysis results show that the complete response rate (CRR) (RR: 2.23, 95% CI: 1. 46 to 3.40, P 0.01), partial response rate (PRR) (RR: −2.25, 95% CI: 1.41 to 3.59, P 0.01), and disease control rate (DCR) (RR: −2.80, 95% CI: 1.64 to 4.80, P< 0.01) of patients with advanced NSCLC who received physical ablation combined with TKI therapy were higher than those who did not receive physical ablation therapy. The control groups from seven of the studies had a total of 606 patients with targeted therapies and chemotherapy. The complete response rate was (CRR) (RR: 2.48, 2.4895% CI: 1.55 to 2.47, P 0.01), partial response rate (PRR) (RR: −1.66, 95% CI: 1.20 to 2.31, P< 0.01), and disease control rate (DCR) (RR: −2.68, 95% CI: 1.41 to 5.06, P< 0.01) for patients with advanced NSCLC who had received physical ablation combined with targeted therapies and chemotherapy, compared to patients who had not received physical ablation therapy. This difference was statistically significant. Above all, these results showed that the clinical efficacy of physical ablation combined EGFR-TKIs therapy (regardless of whether it was combined with chemotherapy) was better than that of EGFR-TKIs therapy alone. CONCLUSION: Physical ablation combined with TKI treatment in patients with advanced NSCLC can improve efficacy.
format Online
Article
Text
id pubmed-8123993
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-81239932021-05-27 Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials Li, Lu-Zhen Wu, Jia-Ming Chen, Ting Zhao, Liang-Chen Zhuang, Juan-Na Hong, Hui-Si Zhang, Ao Zhang, Hua-Tang Fang, Can-Tu Evid Based Complement Alternat Med Research Article OBJECTIVE: Systematically evaluate the efficacy of physical ablation combined with TKI in the treatment of advanced non-small cell lung cancer (NSCLC). METHODS: We performed a comprehensive search of databases including OVID, PubMed, EMBASE, the Cochrane Library, and three Chinese databases (China National Knowledge Infrastructure, Wanfang Database, and Chongqing Weipu Database). The aim was to identify randomized controlled trials (RCT) investigating physical ablation as the treatment for advanced NSCLC. We also evaluated the methodological quality of the included studies and summarized the data extracted for meta-analysis with Review Manager 5.3. RESULTS: A total of 9 studies, including 752 patients, were evaluable. The meta-analysis results show that the complete response rate (CRR) (RR: 2.23, 95% CI: 1. 46 to 3.40, P 0.01), partial response rate (PRR) (RR: −2.25, 95% CI: 1.41 to 3.59, P 0.01), and disease control rate (DCR) (RR: −2.80, 95% CI: 1.64 to 4.80, P< 0.01) of patients with advanced NSCLC who received physical ablation combined with TKI therapy were higher than those who did not receive physical ablation therapy. The control groups from seven of the studies had a total of 606 patients with targeted therapies and chemotherapy. The complete response rate was (CRR) (RR: 2.48, 2.4895% CI: 1.55 to 2.47, P 0.01), partial response rate (PRR) (RR: −1.66, 95% CI: 1.20 to 2.31, P< 0.01), and disease control rate (DCR) (RR: −2.68, 95% CI: 1.41 to 5.06, P< 0.01) for patients with advanced NSCLC who had received physical ablation combined with targeted therapies and chemotherapy, compared to patients who had not received physical ablation therapy. This difference was statistically significant. Above all, these results showed that the clinical efficacy of physical ablation combined EGFR-TKIs therapy (regardless of whether it was combined with chemotherapy) was better than that of EGFR-TKIs therapy alone. CONCLUSION: Physical ablation combined with TKI treatment in patients with advanced NSCLC can improve efficacy. Hindawi 2021-05-07 /pmc/articles/PMC8123993/ /pubmed/34055015 http://dx.doi.org/10.1155/2021/6624429 Text en Copyright © 2021 Lu-Zhen Li et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Lu-Zhen
Wu, Jia-Ming
Chen, Ting
Zhao, Liang-Chen
Zhuang, Juan-Na
Hong, Hui-Si
Zhang, Ao
Zhang, Hua-Tang
Fang, Can-Tu
Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
title Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
title_full Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
title_fullStr Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
title_short Ablation Therapy Combined with EGFR TKIs in the Treatment of Advanced Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
title_sort ablation therapy combined with egfr tkis in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123993/
https://www.ncbi.nlm.nih.gov/pubmed/34055015
http://dx.doi.org/10.1155/2021/6624429
work_keys_str_mv AT liluzhen ablationtherapycombinedwithegfrtkisinthetreatmentofadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT wujiaming ablationtherapycombinedwithegfrtkisinthetreatmentofadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT chenting ablationtherapycombinedwithegfrtkisinthetreatmentofadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT zhaoliangchen ablationtherapycombinedwithegfrtkisinthetreatmentofadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT zhuangjuanna ablationtherapycombinedwithegfrtkisinthetreatmentofadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT honghuisi ablationtherapycombinedwithegfrtkisinthetreatmentofadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT zhangao ablationtherapycombinedwithegfrtkisinthetreatmentofadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT zhanghuatang ablationtherapycombinedwithegfrtkisinthetreatmentofadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials
AT fangcantu ablationtherapycombinedwithegfrtkisinthetreatmentofadvancednonsmallcelllungcancerametaanalysisofrandomizedcontrolledtrials